Collegium Pharmaceutical is a publicly traded specialty pharmaceutical company founded in 2008 and headquartered in Canton, Massachusetts. The company specializes in developing and commercializing pain management medications, with a particular focus on extended-release and abuse-deterrent formulations. Collegium's product portfolio includes Xtampza ER and other pain management therapies designed for patients with chronic pain conditions. Operating with approximately 850 employees, the company combines scientific research with commercial expertise to advance pain management treatment options. Collegium's specialty in abuse-deterrent formulations addresses both therapeutic needs and societal concerns around opioid misuse, positioning the company as an innovator in responsible pain management.
Collegium operates as a mission-driven pharmaceutical company emphasizing scientific excellence and patient outcomes in pain management. The organization maintains the regulatory rigor and compliance standards inherent to pharmaceutical manufacturing and commercialization. As a specialty pharma company, Collegium fosters a research-focused culture with emphasis on innovation in drug formulation and abuse-deterrent technology. The company's work environment reflects typical pharmaceutical industry structures with dedicated teams across research, development, manufacturing, and commercial functions.
40 open now, 40 first appeared in the last 30d.